RxDoctor Payments Data

John Green

Clinical Cardiac Electrophysiology · Meadowbrook, PANPI 1326282864

Payments from drug & device makers

$8,426in general payments, 2019–2025

Across 504 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$907
  • Amgen$806
  • Novartis$803
  • Pfizer$661
  • Sanofi-aventis U.S. LLC$642
  • E.r. Squibb & Sons, L.L.C.$558
  • plus $4K from 30 others

What the payments were for

  • Food & beverage$8,419100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,426 in reported general payments places this provider in the 20th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$259,982
Medicare patients
752
Services billed
4,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$167,412
XareltoRivaroxaban34$47,969
MultaqDronedarone Hcl26$40,217
EntrestoSacubitril/Valsartan33$32,845
JardianceEmpagliflozin18$13,949
Metoprolol Succinate187$3,677
Valsartan22$2,005
Amlodipine Besylate216$1,939
Diltiazem 24hr Er (Xr)Diltiazem Hcl29$1,464
Atorvastatin Calcium133$1,431
Losartan Potassium92$1,152
Carvedilol131$1,108
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$909
Lisinopril62$822
Rosuvastatin Calcium30$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$661$167,412126 claims
Johnson & JohnsonXarelto$907$47,96934 claims
Sanofi-aventis U.S. LLCMultaq$642$40,21726 claims
NovartisEntresto$803$32,84533 claims
Boehringer IngelheimJardiance$356$13,94918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →